Patients with a certain B-cell malignancy and abnormal liver function tests at diagnosis are at risk of shorter overall survival compared with those who have normal liver function. READ MORE
The FDA just announced that it will allow marketing of the first agency-authorized test for use with flow cytometry in order to help in the detection of several leukemias and lymphomas.
Adolescent and young adult survivors of Hodgkin lymphoma may not be receiving the recommended post-treatment care.
Patients with a certain B-cell malignancy and abnormal liver function tests at diagnosis are at risk of shorter overall survival compared with those who have normal liver function.
Combining an anti-CD20 monoclonal antibody with conventional chemotherapy has demonstrated survival benefits in patients with a previously untreated B-cell malignancy.
In a new study, researchers investigated the likelihood of therapy adherence in patients with chronic myeloid leukemia with heavily subsidized Medicare part D plans, compared with those without a subsidy.
A single-agent therapy provides durable remission rates and a high rate of peripheral neuropathy resolution in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Research in Review
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma.
Recent research in the Journal of Clinical Oncology examined outcomes for patients with myeloid malignancies who had vitamin D deficiency before undergoing allogeneic stem cell transplantation.
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia and a specific mutation.
Single-agent immunotherapy in patients with a subtype of diffuse large B-cell lymphoma provides more clinical benefit than conventional therapy.